We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
RNA category is based on mRNA expression levels in the analyzed samples (RNA assay description). The categories include: tissue/cell line enriched, group enriched, tissue/cell line enhanced, expressed in all, mixed and not detected. RNA category is calculated separately for The Cancer Genome Atlas (TCGA) data from cancer tissues and internally generated Human Protein Atlas (HPA) data from normal tissues and cell lines.
TCGA (cancer tissue):
Expressed in all
HPA (cell line):
Expressed in all
HPA (normal tissue):
Expressed in all
Protein evidencei
Protein evidence scores are generated from several independent sources and are classified as evidence at i) protein level, ii) transcript level, iii) no evidence, or iv) not available.
Evidence at protein level
Protein expression normal tissuei
A summary of the overall protein expression pattern across the analyzed normal tissues. The summary is based on knowledge-based annotation.
"Estimation of protein expression could not be performed. View primary data." is shown for genes analyzed with a knowledge-based approach where available RNA-seq and gene/protein characterization data has been evaluated as not sufficient in combination with immunohistochemistry data to yield a reliable estimation of the protein expression profile.
Granular cytoplasmic expression in most cell types.
IMMUNOHISTOCHEMISTRY DATA RELIABILITY
Data reliability descriptioni
Standardized explanatory sentences with additional information required for full understanding of the knowledge-based expression profile.
Antibody staining mainly consistent with RNA expression data.
Reliability score - normal tissuesi
Reliability score (score description), divided into Enhanced, Supported, Approved, or Uncertain, is evaluated in normal tissues and based on consistency between antibody staining pattern, available RNA-Seq and gene/protein characterization data, as well as similarity between independent antibodies targeting the same protein.
Kaplan-Meier plots for all cancers where high expression of this gene has significant (p<0.001) association with patient survival are shown in this summary. Whether the prognosis is favourable or unfavourable is indicated in brackets. Each Kaplan-Meier plot is clickable and redirects to a detailed page that includes individual expression and survival data for patients with the selected cancer.
RNA expression overview shows RNA-seq data from The Cancer Genome Atlas (TCGA).
TCGA dataseti
RNA-seq data in 17 cancer types are reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA). RNA cancer tissue category is calculated based on mRNA expression levels across all 17 cancer tissues and include: cancer tissue enriched, cancer group enriched, cancer tissue enhanced, expressed in all, mixed and not detected. To access cancer specific RNA and prognostic data, click on the cancer name. The cancer types are color-coded according to which type of normal organ the cancer originates from.
Antibody staining in 20 different cancers is summarized by a selection of four standard cancer tissue samples representative of the overall staining pattern. From left: colorectal cancer, breast cancer, prostate cancer and lung cancer. An additional fifth image can be added as a complement. The assay and annotation is described here. Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
For each cancer, color-coded bars indicate the percentage of patients (maximum 12 patients) with high and medium protein expression level. The cancer types are color-coded according to which type of normal organ the cancer originates from. Low or not detected protein expression results in a white bar. Mouse-over function shows details about expression level and normal tissue of origin. The images and annotations can be accessed by clicking on the cancer name or protein expression bar. If more than one antibody is analyzed, the tabs at the top of the staining summary section can be used to toggle between the different antibodies.
Most malignant tissues displayed moderate to strong cytoplasmic immunoreactivity with a granular pattern.
All malignancies showed moderate to strong granular cytoplasmic positivity.
Strong cytoplasmic immunoreactivity, with a granular pattern was observed in cancer tissues.
GENE INFORMATIONi
Gene information from Ensembl and Entrez, as well as links to available gene identifiers are displayed here. Information was retrieved from Ensembl if not indicated otherwise.
Gene name
HSPD1 (HGNC Symbol)
Synonyms
GroEL, HSP60, SPG13
Description
Heat shock protein family D (Hsp60) member 1 (HGNC Symbol)
Entrez gene summary
This gene encodes a member of the chaperonin family. The encoded mitochondrial protein may function as a signaling molecule in the innate immune system. This protein is essential for the folding and assembly of newly imported proteins in the mitochondria. This gene is adjacent to a related family member and the region between the 2 genes functions as a bidirectional promoter. Several pseudogenes have been associated with this gene. Two transcript variants encoding the same protein have been identified for this gene. Mutations associated with this gene cause autosomal recessive spastic paraplegia 13. [provided by RefSeq, Jun 2010]
The protein browser displays the antigen location on the target protein(s) and the features of the target protein. The tabs at the top of the protein view section can be used to switch between the different splice variants to which an antigen has been mapped.
At the top of the view, the position of the antigen (identified by the corresponding HPA identifier) is shown as a green bar. A yellow triangle on the bar indicates a <100% sequence identity to the protein target.
Under the antigens, the maximum percent sequence identity of the protein to all other proteins from other human genes is displayed, using a sliding window of 10 aa residues (HsID 10) or 50 aa residues (HsID 50). The region with the lowest possible identity is always selected for antigen design, with a maximum identity of 60% allowed for designing a single-target antigen (read more).
The curve in blue displays the predicted antigenicity i.e. the tendency for different regions of the protein to generate an immune response, with peak regions being predicted to be more antigenic.The curve shows average values based on a sliding window approach using an in-house propensity scale. (read more).
If a signal peptide is predicted by a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius (turquoise) and/or transmembrane regions (orange) are predicted by MDM, these are displayed.
Low complexity regions are shown in yellow and InterPro regions in green. Common (purple) and unique (grey) regions between different splice variants of the gene are also displayed (read more), and at the bottom of the protein view is the protein scale.
HSPD1-001
HSPD1-006
HSPD1-009
HSPD1-010
HSPD1-011
HSPD1-012
HSPD1-013
HSPD1-201
PROTEIN INFORMATIONi
The protein information section displays alternative protein-coding transcripts (splice variants) encoded by this gene according to the Ensembl database.
The ENSP identifier links to the Ensembl website protein summary, while the ENST identifier links to the Ensembl website transcript summary for the selected splice variant. The data in the UniProt column can be expanded to show links to all matching UniProt identifiers for this protein.
The protein classes assigned to this protein are shown if expanding the data in the protein class column. Parent protein classes are in bold font and subclasses are listed under the parent class.
The Gene Ontology terms assigned to this protein are listed if expanding the Gene ontology column. The length of the protein (amino acid residues according to Ensembl), molecular mass (kDalton), predicted signal peptide (according to a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius) and the number of predicted transmembrane region(s) (according to MDM) are also reported.
Enzymes ENZYME proteins Hydrolases Predicted intracellular proteins Plasma proteins Cancer-related genes Candidate cancer biomarkers Disease related genes Potential drug targets Protein evidence (Kim et al 2014) Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000166 [nucleotide binding] GO:0001530 [lipopolysaccharide binding] GO:0001666 [response to hypoxia] GO:0002020 [protease binding] GO:0002039 [p53 binding] GO:0002236 [detection of misfolded protein] GO:0002368 [B cell cytokine production] GO:0002755 [MyD88-dependent toll-like receptor signaling pathway] GO:0002842 [positive regulation of T cell mediated immune response to tumor cell] GO:0002931 [response to ischemia] GO:0003688 [DNA replication origin binding] GO:0003697 [single-stranded DNA binding] GO:0003723 [RNA binding] GO:0003725 [double-stranded RNA binding] GO:0005515 [protein binding] GO:0005524 [ATP binding] GO:0005615 [extracellular space] GO:0005737 [cytoplasm] GO:0005739 [mitochondrion] GO:0005743 [mitochondrial inner membrane] GO:0005759 [mitochondrial matrix] GO:0005769 [early endosome] GO:0005782 [peroxisomal matrix] GO:0005791 [rough endoplasmic reticulum] GO:0005794 [Golgi apparatus] GO:0005829 [cytosol] GO:0005886 [plasma membrane] GO:0005905 [clathrin-coated pit] GO:0006357 [regulation of transcription from RNA polymerase II promoter] GO:0006457 [protein folding] GO:0006458 ['de novo' protein folding] GO:0006919 [activation of cysteine-type endopeptidase activity involved in apoptotic process] GO:0006986 [response to unfolded protein] GO:0008637 [apoptotic mitochondrial changes] GO:0009408 [response to heat] GO:0009409 [response to cold] GO:0009986 [cell surface] GO:0010033 [response to organic substance] GO:0014070 [response to organic cyclic compound] GO:0014823 [response to activity] GO:0016020 [membrane] GO:0016032 [viral process] GO:0016787 [hydrolase activity] GO:0016887 [ATPase activity] GO:0019907 [cyclin-dependent protein kinase activating kinase holoenzyme complex] GO:0030061 [mitochondrial crista] GO:0030135 [coated vesicle] GO:0030141 [secretory granule] GO:0031012 [extracellular matrix] GO:0031625 [ubiquitin protein ligase binding] GO:0032403 [protein complex binding] GO:0032496 [response to lipopolysaccharide] GO:0032727 [positive regulation of interferon-alpha production] GO:0032729 [positive regulation of interferon-gamma production] GO:0032733 [positive regulation of interleukin-10 production] GO:0032735 [positive regulation of interleukin-12 production] GO:0032755 [positive regulation of interleukin-6 production] GO:0033198 [response to ATP] GO:0042026 [protein refolding] GO:0042100 [B cell proliferation] GO:0042110 [T cell activation] GO:0042113 [B cell activation] GO:0042220 [response to cocaine] GO:0042493 [response to drug] GO:0042542 [response to hydrogen peroxide] GO:0042588 [zymogen granule] GO:0043032 [positive regulation of macrophage activation] GO:0043065 [positive regulation of apoptotic process] GO:0043066 [negative regulation of apoptotic process] GO:0043209 [myelin sheath] GO:0043231 [intracellular membrane-bounded organelle] GO:0043234 [protein complex] GO:0043524 [negative regulation of neuron apoptotic process] GO:0043559 [insulin binding] GO:0043627 [response to estrogen] GO:0044183 [protein binding involved in protein folding] GO:0045041 [protein import into mitochondrial intermembrane space] GO:0045121 [membrane raft] GO:0046696 [lipopolysaccharide receptor complex] GO:0046982 [protein heterodimerization activity] GO:0048291 [isotype switching to IgG isotypes] GO:0050729 [positive regulation of inflammatory response] GO:0050821 [protein stabilization] GO:0050870 [positive regulation of T cell activation] GO:0051082 [unfolded protein binding] GO:0051085 [chaperone mediated protein folding requiring cofactor] GO:0051087 [chaperone binding] GO:0051131 [chaperone-mediated protein complex assembly] GO:0051384 [response to glucocorticoid] GO:0051604 [protein maturation] GO:0051787 [misfolded protein binding] GO:0061077 [chaperone-mediated protein folding] GO:0070062 [extracellular exosome] GO:0071866 [negative regulation of apoptotic process in bone marrow] GO:1903427 [negative regulation of reactive oxygen species biosynthetic process] GO:1904469 [positive regulation of tumor necrosis factor secretion] GO:2000778 [positive regulation of interleukin-6 secretion]
Enzymes ENZYME proteins Hydrolases Predicted intracellular proteins Plasma proteins Cancer-related genes Candidate cancer biomarkers Disease related genes Potential drug targets Protein evidence (Kim et al 2014) Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000166 [nucleotide binding] GO:0001530 [lipopolysaccharide binding] GO:0002039 [p53 binding] GO:0002368 [B cell cytokine production] GO:0002755 [MyD88-dependent toll-like receptor signaling pathway] GO:0002842 [positive regulation of T cell mediated immune response to tumor cell] GO:0003688 [DNA replication origin binding] GO:0003697 [single-stranded DNA binding] GO:0003723 [RNA binding] GO:0003725 [double-stranded RNA binding] GO:0005515 [protein binding] GO:0005524 [ATP binding] GO:0005615 [extracellular space] GO:0005737 [cytoplasm] GO:0005739 [mitochondrion] GO:0005743 [mitochondrial inner membrane] GO:0005759 [mitochondrial matrix] GO:0005769 [early endosome] GO:0005829 [cytosol] GO:0005905 [clathrin-coated pit] GO:0006357 [regulation of transcription from RNA polymerase II promoter] GO:0006457 [protein folding] GO:0006458 ['de novo' protein folding] GO:0006919 [activation of cysteine-type endopeptidase activity involved in apoptotic process] GO:0006986 [response to unfolded protein] GO:0008637 [apoptotic mitochondrial changes] GO:0009409 [response to cold] GO:0009986 [cell surface] GO:0016020 [membrane] GO:0016032 [viral process] GO:0016787 [hydrolase activity] GO:0016887 [ATPase activity] GO:0019907 [cyclin-dependent protein kinase activating kinase holoenzyme complex] GO:0030135 [coated vesicle] GO:0030141 [secretory granule] GO:0031012 [extracellular matrix] GO:0031625 [ubiquitin protein ligase binding] GO:0032727 [positive regulation of interferon-alpha production] GO:0032729 [positive regulation of interferon-gamma production] GO:0032733 [positive regulation of interleukin-10 production] GO:0032735 [positive regulation of interleukin-12 production] GO:0032755 [positive regulation of interleukin-6 production] GO:0042026 [protein refolding] GO:0042100 [B cell proliferation] GO:0042110 [T cell activation] GO:0042113 [B cell activation] GO:0043032 [positive regulation of macrophage activation] GO:0043065 [positive regulation of apoptotic process] GO:0043066 [negative regulation of apoptotic process] GO:0043234 [protein complex] GO:0044183 [protein binding involved in protein folding] GO:0045041 [protein import into mitochondrial intermembrane space] GO:0046696 [lipopolysaccharide receptor complex] GO:0048291 [isotype switching to IgG isotypes] GO:0050821 [protein stabilization] GO:0050870 [positive regulation of T cell activation] GO:0051082 [unfolded protein binding] GO:0051087 [chaperone binding] GO:0051131 [chaperone-mediated protein complex assembly] GO:0051604 [protein maturation] GO:0061077 [chaperone-mediated protein folding] GO:0070062 [extracellular exosome]